MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
Globe Newswire•27/10/2026•08:00 ET
0
Key Highlights
- ➤MeiraGTx announces three ESGCT posters and one NEALS poster for October 27-30 meetings
- ➤AAV-NRF2 completely rescued RPE viability, phagocytic function, and barrier integrity under oxidative stress
- ➤Optimized AAV-hUPF1 reduced construct size 1.5kb while improving efficacy in ALS models
- ➤AAV-hUPF1 improved motor neuron survival to wild-type levels at approximately 36% transduction
- ➤dSEC-MS improved viral protein resolution across AAV2, AAV5, and AAV8 versus reverse-phase LC-MS
LONDON and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit three posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress, which is being held from October 27-30, 2026, in Hamburg, Germany and one poster at the Network of Excellence for ALS (NEALS) Annual Meeting which is being held from October 27-30, 2026, in Clearwater, FL.
The posters will be available on the Posters and Publications page of the Company’s website after their respective conference presentation times.
Get started
Create a free account to read the full story.